Loading
A phase 3 trial testing JNJ-79635322 in multiple myeloma, now recruiting.
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07258511, led by Janssen Research & Development, and recruiting on the registry. Official title: A Phase 3 Randomised Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody. Planned enrolment is 400 participants (estimated). The study started in 2026-02-04 and primary completion is expected in 2028-12-12. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/